National Jewish Health Advanced Diagnostic Laboratories Receives Approval to Test Specimens from Rhode Island
OCTOBER 28, 2014
DENVER, CO — The National Jewish Health Advanced Diagnostic Laboratories were recently licensed to conduct testing on specimens from the State of Rhode Island. The license, issued by the Rhode Island Department of Health, is valid until December 30, 2015.
“We’re excited to be licensed in Rhode Island so we can bring our expertise in specialized testing to more clinical laboratories to help more patients,” said Max Salfinger, MD, Interim Executive Director, Advanced Diagnostic Laboratories, and Director, Mycobacteriology and Pharmacokinetics Laboratory at National Jewish Health. “Our laboratories offer tests that are not offered anywhere else, making us a trusted resource for specialized testing.”
National Jewish Health Advanced Diagnostic Laboratories perform a wide variety of diagnostic tests covering many specialty areas including: tuberculosis, nontuberculous mycobacteria (NTM) and other infectious diseases, as well as infectious disease therapeutic drug monitoring, genome analysis for cystic fibrosis, immunodeficiency, immunology and complement activation.
The laboratory is CLIA, CAP, and ISO 15189 accredited and performs GLP testing upon request.
National Jewish Health is the leading respiratory hospital in the nation. Founded 119 years ago as a nonprofit hospital, National Jewish Health today is the only facility in the world dedicated exclusively to groundbreaking medical research and treatment of patients with respiratory, cardiac, immune and related disorders. Patients and families come to National Jewish Health from around the world to receive cutting-edge, comprehensive, coordinated care. To learn more, visit the media resources page.